ImaCor Inc., developer of the first and only hemodynamic transesophageal echocardiographic (hTEE™) management device, is now receiving orders from hospitals within the Tenet, HCA, and Department of Veteran Affairs (VA) systems.
Since commercially launching the ClariTEE® probe and Zura™ system in early 2010, ImaCor has provided hTEE management solutions to renowned medical centers such as Vanderbilt University, University of Alabama, and Barnes-Jewish. The positive impact of hTEE management has been cited in studies from various disciplines including those involved in trauma, sepsis, cardiac surgery, and high-risk anesthesia care.
Unique from traditional TEE, the ClariTEE is optimized for ease of use and repeatability with constant availability in critical care and operative settings. It provides real-time visualization of cardiac filling and function, and may remain indwelling for up to 72-hours while medical interventions are made.
"We are delighted that the clinical efficacy of our hTEE technology and ClariTEE probe resonates with physicians at hospitals within these three premier group purchasing systems," said Dipak Rajhansa, Vice President of Sales & Marketing. "We look forward to growing our relationships with these entities to make this essential management solution more accessible within the critical care arena."
ImaCor Inc. is a privately held company headquartered in Garden City, NY. The company designs, manufactures, and distributes advanced solutions for hemodynamic assessment in the critical care environment for the purpose of improving patient outcomes and optimizing utilization of healthcare costs. ImaCor manufactures the ClariTEE® probe, the only miniaturized, indwelling TEE probe suitable for long-term clinical settings. hTEE™, Zura™ and ClariTEE® are trademarks of ImaCor, Inc. http://www.imacorinc.com.